is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to rkh@federmanlaw.com or fax to (405) 239-2112. 

Current Cases

Ocular Therapeutix, Inc. [NASDAQ: OCUL]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Ocular Therapeutix, Inc.

Oklahoma City, OK (July 11, 2017) – On July 7, 2017, a securities class action lawsuit was filed in the United States District Court for the District of New Jersey against Ocular Therapeutix, Inc. (NASDAQ: OCUL). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is May 5, 2017 through July 6, 2017. More specifically, this litigation was filed because oMay 5, 2017, Ocular disclosed that the U.S. Food and Drug Administration (“FDA”) had found minor issues at its manufacturing plant. However, on July 6, 2017, an article published by Seeking Alpha claimed that Ocular’s management had been misleading investors about manufacturing issues. One of the claims made by the article is “that more than 50% of lots manufactured by OCUL contain bad product.”

Following this news, Ocular’s shares fell $0.68 per share to close at $9.50 per share on July 6, 2017.

Plaintiff seeks to recover damages on behalf of all Ocular Therapeutix, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, September 5, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to rkh@federmanlaw.com, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.